Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies

NCT05207670 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05207670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05207670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2022
Completion date
July 31, 2027
Enrollment
320 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma